Security key
254604101
Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON)
CUSIP: 254604101
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 37,778,373
- Total 13F shares
- 33,154,047
- Share change
- +6,503,901
- Total reported value
- $1,649,828,469
- Put/Call ratio
- 21%
- Price per share
- $49.64
- Number of holders
- 155
- Value change
- +$313,979,403
- Number of buys
- 98
- Number of sells
- 51
Report period
Q1 2025
Institutions
155
Top holders
10
IRON full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Disc Medicine, Inc. SEC filings
Disc Medicine, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 254604101
Recent filing periods:
Top shareholders of IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
|
Company · Director |
4.5%
from 13D/G
|
1,785,571
|
$113,205,201 | — | 31 Dec 2024 | |
| Paradigm Biocapital Advisors LP |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
1,497,720
|
$94,955,448 | — | 31 Dec 2024 | |
| Bain Capital Life Sciences Opportunities III, LP |
13D/G
|
— |
3.3%
|
983,500
|
$46,372,025 | $0 | 31 Dec 2024 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
6.6%
|
2,509,456
|
$159,099,510 | — | 31 Dec 2024 | |
| FMR LLC |
13F
|
Company |
4.9%
|
1,866,248
|
$118,320,123 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
4.9%
|
1,859,732
|
$117,907,008 | — | 31 Dec 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
4.6%
|
1,754,834
|
$111,256,476 | — | 31 Dec 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.7%
|
1,395,405
|
$88,468,676 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.7%
|
1,394,637
|
$88,421,000 | — | 31 Dec 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.2%
|
1,217,815
|
$77,170,328 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.8%
|
1,068,246
|
$67,726,796 | — | 31 Dec 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
2.6%
|
983,500
|
$62,353,900 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
768,735
|
$48,737,799 | — | 31 Dec 2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.6%
|
600,515
|
$38,072,651 | — | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
591,271
|
$37,486,581 | — | 31 Dec 2024 | |
| Saturn V Capital Management LP |
13F
|
Company |
1.3%
|
509,406
|
$32,296,340 | — | 31 Dec 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.3%
|
486,957
|
$30,873,074 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
472,706
|
$29,976,215 | — | 31 Dec 2024 | |
| Woodline Partners LP |
13F
|
Company |
1%
|
396,600
|
$25,144,440 | — | 31 Dec 2024 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.94%
|
356,000
|
$22,570,400 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.93%
|
350,000
|
$22,190,000 | — | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.92%
|
346,401
|
$21,961,823 | — | 31 Dec 2024 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.79%
|
299,069
|
$18,960,975 | — | 31 Dec 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.63%
|
236,244
|
$14,977,870 | — | 31 Dec 2024 | |
| Logos Global Management LP |
13F
|
Company |
0.53%
|
200,000
|
$12,680,000 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.5%
|
187,017
|
$11,856,877 | — | 31 Dec 2024 | |
| Checkpoint Capital L.P. |
13F
|
Company |
0.49%
|
185,000
|
$11,729,000 | — | 31 Dec 2024 | |
| Catalio Capital Management, LP |
13F
|
Company |
0.48%
|
179,815
|
$11,400,271 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.45%
|
171,810
|
$10,892,754 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.44%
|
165,072
|
$10,465,565 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.4%
|
150,024
|
$9,511,563 | — | 31 Dec 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.4%
|
150,000
|
$9,510,000 | — | 31 Dec 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.37%
|
139,720
|
$8,855,864 | — | 31 Dec 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.34%
|
129,482
|
$8,209,159 | — | 31 Dec 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.32%
|
120,260
|
$7,624,484 | — | 31 Dec 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.29%
|
110,381
|
$6,998,155 | — | 31 Dec 2024 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.25%
|
93,103
|
$5,902,731 | — | 31 Dec 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.24%
|
91,490
|
$5,635,784 | — | 31 Dec 2024 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.23%
|
88,002
|
$5,579,326 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.23%
|
86,420
|
$5,479,028 | — | 31 Dec 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.21%
|
81,190
|
$5,147,446 | — | 31 Dec 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.2%
|
77,050
|
$4,884,970 | — | 31 Dec 2024 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.19%
|
73,511
|
$4,660,597 | — | 31 Dec 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.18%
|
69,072
|
$4,379,165 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.16%
|
61,017
|
$3,868,478 | — | 31 Dec 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
57,261
|
$3,630,348 | — | 31 Dec 2024 | |
| Patient Square Capital LP |
13F
|
Company |
0.15%
|
56,400
|
$3,575,760 | — | 31 Dec 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.13%
|
50,121
|
$3,177,671 | — | 31 Dec 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.12%
|
44,932
|
$2,848,689 | — | 31 Dec 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.11%
|
42,635
|
$2,703,059 | — | 31 Dec 2024 |
Institutional Holders of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) as of Q1 2025
As of 31 Mar 2025,
Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) was held by
155 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,154,047 shares.
The largest 10 holders included
FMR LLC, Atlas Venture Life Science Advisors, LLC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Inc., Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, ORBIMED ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, and VANGUARD GROUP INC.
This page lists
155
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
151
Q1 2025 holders
155
Holder diff
4
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.